BIOMAT Database Logo BIOMAT Database Logo

[Efficacy of intravenous dichloromethylene diphosphonate in paraneoplastic hypercalcemia resistant to mithramycin]. 1984

R Peyron, and D Sereni, and G Grateau, and A Boissonnas, and G A Cremer, and C Laroche

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D008297 Male Males
D008926 Plicamycin A tricyclic pentaglycosidic antibiotic from Streptomyces strains that inhibits RNA and protein synthesis by adhering to DNA. It is used as a fluorescent dye and as an antineoplastic agent, especially in bone and testicular tumors. Plicamycin is also used to reduce hypercalcemia, especially that due to malignancies. Aureolic Acid,Mithramycin,Mitramycin
D010257 Paraneoplastic Syndromes In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products. Paraneoplastic Syndrome,Syndrome, Paraneoplastic,Syndromes, Paraneoplastic
D004002 Clodronic Acid A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. Clodronate,Dichloromethylene Diphosphonate,Bonefos,Cl2MDP,Clodronate Disodium,Clodronate Sodium,Dichloromethane Diphosphonate,Dichloromethanediphosphonate,Dichloromethanediphosphonic Acid,Dichloromethylene Biphosphonate,Dichloromethylenebisphosphonate,Acid, Clodronic,Acid, Dichloromethanediphosphonic,Biphosphonate, Dichloromethylene,Diphosphonate, Dichloromethane,Diphosphonate, Dichloromethylene,Disodium, Clodronate,Sodium, Clodronate
D004164 Diphosphonates Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents. Bisphosphonate,Bisphosphonates
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006934 Hypercalcemia Abnormally high level of calcium in the blood. Milk-Alkali Syndrome,Hypercalcemias,Milk Alkali Syndrome,Syndrome, Milk-Alkali
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

R Peyron, and D Sereni, and G Grateau, and A Boissonnas, and G A Cremer, and C Laroche
Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.
March 1981, Annals of internal medicine,
R Peyron, and D Sereni, and G Grateau, and A Boissonnas, and G A Cremer, and C Laroche
Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate.
June 1982, The American journal of medicine,
R Peyron, and D Sereni, and G Grateau, and A Boissonnas, and G A Cremer, and C Laroche
Hypercalcemia in malignancies: treatment with dichloromethylene diphosphonate (Cl2MDP).
February 1985, Tumori,
R Peyron, and D Sereni, and G Grateau, and A Boissonnas, and G A Cremer, and C Laroche
[Preoperative normalization of hypercalcemia, caused by parathyroid cancer, by intravenous administration of dichloromethylene diphosphonate].
January 1984, Minerva endocrinologica,
R Peyron, and D Sereni, and G Grateau, and A Boissonnas, and G A Cremer, and C Laroche
[Neoplastic hypercalcemia with renal insufficiency: treatment with dichloromethylene diphosphonate].
November 1985, La Clinica terapeutica,
R Peyron, and D Sereni, and G Grateau, and A Boissonnas, and G A Cremer, and C Laroche
Chronic lymphocytic leukemia and hypercalcemia: treatment with dichloromethylene diphosphonate.
January 1983, Metabolic bone disease & related research,
R Peyron, and D Sereni, and G Grateau, and A Boissonnas, and G A Cremer, and C Laroche
Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
May 1980, The Journal of clinical investigation,
R Peyron, and D Sereni, and G Grateau, and A Boissonnas, and G A Cremer, and C Laroche
Iv dichloromethylene diphosphonate in cancer-associated hypercalcemia: a phase I-II evaluation.
January 1981, Cancer treatment reports,
R Peyron, and D Sereni, and G Grateau, and A Boissonnas, and G A Cremer, and C Laroche
Repopulation of murine Kupffer cells after intravenous administration of liposome-encapsulated dichloromethylene diphosphonate.
October 1996, The American journal of pathology,
R Peyron, and D Sereni, and G Grateau, and A Boissonnas, and G A Cremer, and C Laroche
Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
August 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Copied contents to your clipboard!